Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
Status:
Not yet recruiting
Trial end date:
2026-03-10
Target enrollment:
Participant gender:
Summary
This study aims to investigate the efficacy and safety of neoadjuvant Toripalimab combined
with Nimotuzumab in primary limited stage oral squamous cell carcinoma prior to radical
therapy.